ArticleEuropean urology2018

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Christopher C Parker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.